*Clinical trial of MK-2214 in people with Early Alzheimer’s Disease

• Research type

  Research Study

• Full title

  A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease

• IRAS ID

  1011934

• Contact name

  - -

• Contact email

  N/A

• Sponsor organisation

  Merck Sharp & Dohme LLC

• Clinicaltrials.gov Identifier

  NCT07033494

• Research summary

  Researchers are looking for new ways to treat Alzheimer’s disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), decision-making skills and can limit a person’s ability to do daily tasks. AD may get worse when a protein called tau forms and collects in brain cells and then spreads to more parts of the brain. Researchers want to know if the trial treatment called MK-2214 works to slow certain changes in the brains of people with AD.

  The goals of the trial are to learn:
  • If MK-2214 slows the spread of tau in the brain compared to placebo (looks
  like the trial treatment but has no trial treatment in it).
  • About the safety of MK-2214 and if people tolerate it

  About 340 people, aged 50 to 85 years old with AD will be in this trial. They can be in this trial if they have mild changes in memory or thinking ability caused by AD and do not have other types of dementia or brain diseases outside of AD. Each person will have a trial partner who will go with them to certain trial visits and answer trial questions. The trial partner will be someone who knows the person’s ability to do daily tasks.

  People will be assigned by chance to receive one of these:
  • MK-2214
  • Placebo
  People will receive the trial treatment or placebo into a vein as an intravenous (IV) infusion once a month for about 2 years.

  People will have a 3 out of 5 chances of getting MK-2214 and a 2 out of 5 chances of getting placebo. Neither the people in the trial nor the researchers will know the trial treatment a person receives (double-blind trial).

  People may be in this trial for about 2 and a half years.

• REC name

  Wales REC 2

• REC reference

  25/WA/0127

• Date of REC Opinion

  24 Jun 2025

• REC opinion

  Further Information Favourable Opinion